NEOGNeogen Corp.

Upcoming Earnings

We were not able to find an announced earnings date for this symbol yet. Check back again later

Company Info

CEO

John E. Adent

Location

Michigan, USA

Exchange

Nasdaq

Website

https://neogen.com

Summary

Neogen Corporation develops, manufactures, and markets various products for food and animal safety worldwide.

Company Info

CEO

John E. Adent

Location

Michigan, USA

Exchange

Nasdaq

Website

https://neogen.com

Summary

Neogen Corporation develops, manufactures, and markets various products for food and animal safety worldwide.

AI Insights for NEOG
6 min read

Quick Summary

Neogen Corporation is a Lansing, Michigan-based company that develops, manufactures, and markets products focused on food safety and animal safety. Its Food Safety segment sells diagnostic test kits and related products used to detect pathogens, allergens, toxins, residues, sanitation issues, and other unintended substances in food and production environments. Its Animal Safety segment sells veterinary instruments, pharmaceuticals, vaccines, topicals, rodenticides, cleaners, disinfectants, insecticides, diagnostics, and related animal health products. The company serves food processors, agricultural producers, livestock operators, veterinarians, laboratories, distributors, and public or private testing organizations. Neogen’s business is global, but its results are closely tied to customer spending in food production, animal agriculture, diagnostics, and regulated safety testing markets. The company is currently in a turnaround phase as it works through integration challenges, debt reduction, margin improvement, and portfolio simplification after major strategic changes.

Strengths

•

Neogen’s primary strength is its focused position in food safety and animal safety, two markets supported by regulation, public health needs, and long-term demand for safer supply chains.

•

The company has a broad product portfolio that allows it to serve food processors, laboratories, veterinarians, livestock producers, and agricultural distributors.

•

Its diagnostic test kits and safety products are tied to customer workflows where reliability and compliance matter, which can create recurring demand when products perform well.

•

Neogen also benefits from global exposure and a recognized brand within specialized food and animal safety niches.

•

The planned GeneSeek divestiture could strengthen the balance sheet by providing cash to reduce debt and simplify the operating structure.

Key Risks

•

Neogen faces execution risk because its turnaround depends on improving margins, integrating acquired operations, simplifying the portfolio, and reducing debt.

•

If the company cannot reverse revenue declines in Food Safety and Animal Safety, investors may question the durability of its core business.

•

Debt and cash burn are major concerns because weak free cash flow can limit strategic flexibility and increase pressure during downturns.

•

Product quality problems, such as the HYCOAT recall, could damage customer trust, trigger regulatory scrutiny, or create unexpected costs.

What to Watch

The most recent quarter included disappointing operating results and continued evidence that Neogen’s turnaround is still incomplete.
Reported fiscal Q3 revenue was $220.98 million, down 3.4% year over year and below the $223.03 million estimate.
Adjusted EPS was reported at $0.10 versus $0.12 a year earlier and below the $0.13 consensus estimate.
Food Safety revenue declined 3.2% to $152.73 million, while Animal Safety revenue declined 4% to $68.25 million.
Neogen also dealt with a product recall involving all in-date HYCOAT after microbial contamination was found in some vials, although the financial hit was described as limited.
The company also announced a major portfolio action by agreeing to sell the GeneSeek global genomics business to Zoetis for $160 million, with proceeds expected mainly to reduce debt.

Price Drivers

•

Neogen’s stock price is being driven primarily by weak earnings, revenue misses, integration progress, debt reduction plans, and investor confidence in the turnaround.

•

The company recently reported revenue below expectations, with fiscal Q3 revenue down 3.4% year over year and both Food Safety and Animal Safety declining.

•

EPS also missed consensus, which reinforced concerns about margin pressure and execution risk.

•

The stock has been volatile, with reported declines of 28.8% over one month in one update and 36.5% to $10.42 in another article.

•

Valuation remains a debate because the company has a market capitalization of about $2.3 billion, a price-to-book value near 1.1, negative EPS, and enterprise-value multiples that still require improved profitability to justify.

•

The planned $160 million sale of GeneSeek to Zoetis is a positive potential catalyst because proceeds are expected to reduce debt and simplify operations.

•

However, high beta of 1.86, negative net income, cash burn concerns, and mixed analyst sentiment can amplify share-price moves around earnings and corporate updates.

Recent News

•

Recent news has been mixed to negative for Neogen, with weak earnings and strategic changes dominating the story.

•

The company reported fiscal Q3 revenue of $220.98 million, down 3.4% year over year and below expectations, while EPS also missed consensus.

•

Shares reportedly fell sharply after the results, and one article noted the stock was down 28.8% over the prior month with a Zacks Sell rating.

•

Neogen also recalled all in-date HYCOAT after microbial contamination was found in some vials, although the approved topical wound-use financial impact was described as limited.

•

On the positive side, Neogen agreed to sell its global genomics business, GeneSeek, to Zoetis for $160 million, with proceeds expected mainly to reduce debt.

•

The company also named Bryan Riggsbee as CFO and SVP effective November 3, 2025, a move investors may view as important for improving execution and financial discipline.

Market Trends

•

The food safety and animal safety markets are shaped by regulation, consumer awareness, supply chain complexity, and the need to prevent contamination or disease outbreaks.

•

Food manufacturers are under pressure to test more consistently for pathogens, allergens, sanitation failures, and quality problems, which supports long-term demand for diagnostics.

•

At the same time, customers are sensitive to cost, efficiency, and workflow automation, which favors suppliers that can offer reliable tests with faster turnaround and lower total operating cost.

•

Animal health markets are influenced by livestock economics, veterinary spending, disease prevention, biosecurity, and agricultural commodity cycles.

•

The broader medical devices and diagnostics group has shown mixed results, with some companies beating expectations while Neogen lagged and saw its shares sell off.

•

Higher interest rates, investor preference for profitable companies, and scrutiny of debt-heavy balance sheets can pressure companies like Neogen until they show stronger cash generation.

AI-generated summary for educational purposes only. Not investment advice. Always do your own research before investing.

Community Research

Research from investors like you

Be the first to share your analysis on NEOG

Help fellow investors make informed decisions by sharing your research on fundamentals, catalysts, and outlook.

Topics: Company overview • Products • Competitors • Strengths & Risks

Symbol's posts

avatar
@ShallowLoving 7 months ago

Market notes: Oil hits $114 on Iran tensions, stagflation fears, and AI job concerns

Market notes: Oil hits $114 on Iran tensions, stagflation fears, and AI job concerns

post thumbnail
avatar
@starcahier 7 months ago

Markets up slightly despite Iran tensions, tech struggles, and JPM warns Tesla could drop 60%

Markets up slightly despite Iran tensions, tech struggles, and JPM warns Tesla could drop 60%

post thumbnail
avatar
@Simonwhite 10 months ago

Neogen Corporation is having a massive day

Neogen Corporation is having a massive day

it's pretty wild to see Neogen Corporation jumping 28% in a single session. i've been looking into lately and the demand for food safety testing seems like a really interesting trend to follow. do you think this growth is here to stay or are people just reacting to the news?

No more topics to show